In this issue:
Daratumumab monotherapy in treatment-refractory MM
Clinical utility of CTX-1 in MM
Targeting proteasome ubiquitin receptor Rpn13 in MM
Oral ixazomib, lenalidomide and dexamethasone for MM
Triplet vs. doublet lenalidomide-containing regimens in elderly MM
PET/CT focal, not osteolytic, lesions predict smouldering
MM progression to active MM
Outcomes of MM patients treated with HSCT vs. conventional chemotherapy
Please login below to download this issue (PDF)